We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Health Canada's Orphan Drug Pilot Project Seeks Patient Involvement

Health Canada's Orphan Drug Pilot Project Seeks Patient Involvement

HealthCanada_Logo.gif
August 13, 2014

Drugmakers Hoffman-La Roche and Hyperion Therapeutics are taking part in Health Canada’s new orphan drugs pilot project to better understand how patient input may be gathered and incorporated into the drug submission review process.

Both companies say that bringing the patient perspective into reviews of drugs for rare diseases is crucial, as patients increasingly are playing an important role in general drug approvals and health technology assessments. The pilot will tap Hoffman-La Roche’s Gazyva (obinutuzumab) for chronic lymphocytic leukemia and Hyperion’s Ravicti (glycerol phenylbutyrate) for urea cycle disorders.

Patients will be asked how their diseases affect the management of day-to-day life, what treatments are available, which ones are most important to them and their tolerance for risks of any new treatments, the agency said this week.

The pilot is expected to last a year and additional companies may join as time progresses, agency spokesman Gary Holub said.

The focus on patient input will add context to the regulatory review process, Canadian Organization for Rare Disorders (CORD) spokesman Durhane Wong-Rieger said. Most regulators have little familiarity with the diseases in question and little experience reviewing drugs to treat them.

Canada Minister of Health Rona Ambrose said regulators are committed to making the experiences and perspectives of patients an important addition to the scientific assessment of drugs for rare diseases.

The pilot is part of a larger initiative to revamp Canada’s orphan drug review process. Only about 60 percent of orphan drugs make it to regulatory approval in Canada, and sometimes up to six years later than in the U.S., says CORD.

Development of a new framework to address orphan drug reviews began in 2012 and was designed to encourage Canadian and international researchers and regulators to share information. But official approval and launch of the framework has been delayed many times, CORD said.

Once the framework goes online, it would let drug companies apply to bring their treatments to Canada at the same time as the USA and Europe, and create an opportunity for Canadians to participate in clinical trials at the same time as they occur worldwide. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Regulatory Affairs Submissions and Approvals

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

  • Eli Lilly logo

    Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

  • CE mark

    Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing